Emylcamate

Emylcamate

Emylcamate is a carbamate derivative used as an anxiolytic. It was patented in the 1960s by Wallace Laboratories and was marketed under the trade name Striatran. However, it was withdrawn from the market in the 1970s due to the potential for abuse and addiction.

Pharmacology

Emylcamate is believed to act as a GABA receptor agonist, similar to other drugs in the carbamate class. This would make it a depressant of the central nervous system. However, the exact mechanism of action is not fully understood.

Medical uses

Emylcamate was used for the short-term treatment of anxiety and tension. However, it is no longer marketed due to concerns about its potential for abuse and addiction.

Side effects

The side effects of emylcamate are similar to those of other GABAergic drugs, including drowsiness, dizziness, and confusion. In rare cases, it can cause more serious side effects such as respiratory depression and dependence.

History

Emylcamate was first synthesized in the 1960s by Wallace Laboratories. It was marketed under the trade name Striatran for the treatment of anxiety and tension. However, it was withdrawn from the market in the 1970s due to concerns about its potential for abuse and addiction.

See also

• Carbamate
• Anxiolytic
• GABA receptor
• Depressant
• Central nervous system
• Anxiety
• GABAergic
• Respiratory depression
• Dependence

This article is a stub related to pharmacology. You can help WikiMD by expanding it!